117 results about "Functional disorder" patented technology

A rehabilitation evaluation system for a patient with central nervous system dysfunction comprises the following steps of S1, collecting videos, motion data and pressure data of a user through a data collection layer, S2, uploading the video data to an edge computing server, performing preliminary posture estimation, and S3, performing rehabilitation evaluation. The method comprises the following steps: S1, carrying out edge calculation on the data, S3, transmitting the data subjected to edge calculation to a cloud server for deep modeling analysis of gait and balance parameters, S4, carrying out abnormal mode identification and comparison after parameter analysis, S5, uploading the analyzed data after comparison to a decision application layer, S6, transmitting each parameter and a corresponding processing scheme to a doctor end for a doctor to check, and S5, carrying out data processing. The method has the advantages that through full-link innovation of multi-mode lightweight acquisition, edge cloud hierarchical processing, double-model intelligent diagnosis, reinforcement learning dynamic optimization and visual remote decision, central nervous rehabilitation evaluation extends to a daily life scene from a laboratory, and core breakthrough of precision improvement, efficiency multiplication and personalized enhancement is achieved.

Methods, systems, and devices, including computer programs encoded on a computer storage medium are provided for optimizing neurostimulation therapy for treatment of neurological and neurodegenerative diseases. Joint dynamic causal modeling and biophysics modeling are used for optimization of the stimulation targets and parameters. In particular, methods of performing neuromodulation to suppress b-band oscillations in the brain of a subject are provided.

The invention discloses construction and application of a Primrose syndrome non-human animal model, and belongs to the technical field of animal models and disease research. According to the invention, through a CRISPR / Cas9 technology, a codon CAC for coding 596th histidine in a No.14 exon of a mouse Zbtb20 gene is subjected to site-directed mutagenesis into CGC for coding arginine, and a hybrid mouse model for simulating pathogenic point mutation (p.H596R) of human Primrose syndrome is constructed. The model can stably reproduce key clinical phenotypes of the Primrose syndrome, including overgrowth after adult, serum IGF-1 rise, memory dysfunction and anxiety behaviors, and shows abnormal hippocampal neuronal development and synaptic transfer related pathways and the like. The invention provides an important experimental tool for deeply revealing the pathological mechanism of Primrose syndrome, developing drug screening and treatment intervention research and the like.

Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to septic shock in pediatric patients. Certain aspects of the disclosure relate to identifying one or more biomarkers associated with septic shock in pediatric patients in combination with one or more endothelial-derived biomarkers, obtaining a sample from a pediatric patient having at least one indication of septic shock, then quantifying from the sample an amount of said biomarkers, wherein the level of said biomarker correlates with a predicted outcome.

The invention discloses a traditional Chinese and western medicine cooperative emotion nursing management system and a physiotherapy robot applying the same, and aims to solve the technical problems in the aspects of traditional Chinese and western medicine theory deep cooperation and dynamic personalized nursing in the prior art. The system is realized through the following steps: collecting physiological, behavior, traditional Chinese medicine and other multi-modal data of a user, and constructing a unified traditional Chinese and western medicine cooperative emotional state vector; reasoning by using a traditional Chinese and western medicine fusion knowledge graph to generate an interpretable traditional Chinese medicine macroscopic treatment target; a double-layer hierarchical reinforcement learning model is adopted for decision making, a macroscopic intervention combination is generated through a high-layer strategy, and an accurate robot control instruction containing emotional tactile parameters is generated through a low-layer strategy; and finally, driving the physiotherapy robot to execute the instruction, and continuously optimizing the strategy through closed-loop feedback. According to the method, the artificial intelligence decision theory and the traditional Chinese medicine syndrome differentiation treatment thought are combined, and an automatic and emotional traditional Chinese and western medicine cooperative nursing solution is provided for mood-related functional disorders.

The disclosed invention is a method for mapping glutathione deficiency and / or mitochondria dysfunction in disease states, utilizing glutathione and its precursors as imaging tracers in conjunction with medical imaging techniques, particularly magnetic resonance imaging. The innovation involves administering glutathione or glutathione-increasing interventions, such as oral liposomal reduced glutathione, to enhance imaging accuracy. The proposed methodology aims to identify and monitor regions of depleted reduced glutathione (GSH) in various organs and tissues. The maps generated through this process provide valuable biomarkers for toxic exposure, early biological effects, and health risks. The approach is versatile, offering applications in mental health, neurological disorders, inflammation, organ dysfunction, and personalized treatment and risk assessments.

The invention relates to the technical field of data processing, in particular to a spinal disease intelligent confirmation method, device and equipment, and the method comprises the steps: firstly constructing a multi-modal spatio-temporal data set fusing a static structure, a dynamic function and clinical data, and carrying out the standardization processing; the method comprises the steps that firstly, through a pre-trained HMC-VSPF heterogeneous modal collaborative awareness and centrum sequence conduction fusion network, quantitative prediction of symptom severity is achieved, the contribution degree of structural lesions and dysfunction to symptoms is quantified, finally, through unsupervised clustering fused with biomechanical constraints, intelligent typing of pathogenic modes is achieved, and the probability of pathopoiesis is lowered. And an individualized diagnosis and treatment data product is generated through three-level quality control. Through multi-modal data deep fusion, causal mechanism analysis and intelligent typing, the diagnosis and treatment accuracy and interpretability are improved, individualized precise diagnosis and treatment of spinal diseases are achieved, and a quantitative basis is provided for clinical decision making.

The present application relates to a kind of pituitary adenoma simulation teaching method, one aspect, in the case of unified time axis, with the volume of pituitary adenoma as the basis, the hormone level change of corresponding hormone species and visual change condition are associated, can clearly know the curve and numerical value of GH, PRL, ACTH, cortisol and other key hormones, the condition of real-time change with tumor state change, and the real-time synchronization of visual field change and the increase and decrease of tumor size, strengthen the understanding of "space-occupied effect-dysfunction" correlation of the trainee, and the degree of oppression of pituitary adenoma to surrounding tissue is quantified by pressure sensor, the compression phenomenon of pituitary adenoma volume change is directly reflected;Another aspect, for a large number of hormone species data, through the preset data ROI search algorithm, the position of data weak fluctuation can be accurately found, and the corresponding volume change moment of pituitary adenoma helps trainee to locate quickly key time point, improves learning efficiency.

The application discloses a mouse vitiligo induction model based on chronic stress factors, wherein different kinds of stress factors capable of triggering stress response of animals are applied to stimulate the mouse periodically within a certain time period, so as to prevent the mouse from producing habitual response to the stress source and to promote the mouse to become white and the tail epidermis to be flaky. The technical method is different from the existing vitiligo model method, is based on the mechanism of occurrence and development of vitiligo observed in the clinic, and promotes the mouse to truly develop the vitiligo phenomenon from the whole instead of simulating the disease evolution locally. Compared with the existing vitiligo promoting mechanism, the effect is more stable and the authenticity is higher. The technical method is based on the objective fact that the clinical vitiligo patients often combine anxiety and depression to design the stress factors, and considers that the stress factors and the occurrence and development of vitiligo may be inter-caused and viciously circulate, namely, the adverse life events as the stress factors cause the damage and dysfunction of the melanin synthesis system at the micro level and form the vitiligo change at the macro level.

Described herein are methods for disease or disorder associated with GABA transporter 1 (GAT-1) dysfunction. In one aspect described herein, the disease or disorder is associated with one or more solute carrier Family 6 Member 1 (SLC6A1) mutations, and 4-phenylbutyrate, or the pharmaceutically acceptable salt thereof, is administered at a dose of 75 mg / kg / day to 125 mg / kg / day. In another embodiment, the method comprises combined GAT-1 gene therapy combined with administration of 4-phenylbutyrate.

The present invention relates to splice variants of the CERT1 protein that act as biomarkers for TDP-43 pathology, particularly motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD), as well as other neurological diseases such as Alzheimer's disease. In particular, the present invention relates to a method for identifying splice variants of CERT1 comprising cryptic peptide sequences, as well as related methods for identifying TDP-43 pathology and / or TDP-43 dysfunction in a subject, and a method for predicting the likelihood of successful treatment. Antibodies that bind to CERT1 splice variants and kits comprising said antibodies are also claimed.

In nerve diseases, cell dysfunction due to amyloid aggregate accumulation in nerve cells has attracted attention, but dysfunction of nerve axons responsible for neurotransmission is also considered to be one of the causes. However, no therapeutic agent that focuses on the repair and maintenance of nerve axons has been found. An object of the present invention is to provide a therapeutic agent that activates oligodendrocytes having a function of preserving nerve axons.SOLUTION: Transcriptome analysis with a psychotropic drug is carried out using an oligodendrocyte marker as an indicator, and it is found that the combined use of DPZ and NFN characteristically increases the expression of a transcriptional factor OLIG1 inducing the differentiation-maturation of the oligodendrocyte. Moreover, the drug concentration at this time was much lower than the expected clinical dose. The combined use of NFN and DPZ was observed to improve spatial memory in the mouse Y-maze test. The combination of NFN and DPZ can provide a novel treatment for cognitive and memory functions associated with neurological disorders.SELECTED DRAWING: None

The invention belongs to the technical field of medical experimental animal models, provides a construction method of a dry age-related macular degeneration animal model, and aims to break through the technical bottlenecks of long construction period, high cost and incomplete pathological feature coverage of an existing model. D-galactose is used for inducing glycosylation end product accumulation and mitochondrial dysfunction, oxidative stress, RPE metabolic disorder and inflammation microenvironment in the dry AMD pathogenesis process can be synchronously simulated, core pathological characteristics such as retina glass membrane wart deposition, RPE atrophy, retina and visual function damage and the like can be accurately reproduced, meanwhile, a multi-dimensional verification system is matched, and the method has the advantages that the method is simple and convenient to operate and high in practicability. The method is suitable for preclinical evaluation of personalized treatment strategies; besides, the method is short in modeling period, the animal model meeting the requirement can be obtained within 8 weeks, the cost advantage is outstanding, and an efficient and reliable experimental animal model can be provided for dry AMD treatment research.

The present disclosure relates to Sigma-1 receptor agonists, and their target engagement and capacity to correct multiple EEG biomarkers of cortical dysfunction. The present disclosure further provides Precision Medicine or personalized therapy of using a Sigma-1 receptor agonist in treating neurodevelopmental and / or neurodegenerative disorder through engaging with EEG biological pathways. Also provided are kits for practicing the methods.

This invention discloses an active five-tone speech therapy system, primarily targeting individuals with speech dysfunction after stroke. Its core active five-tone speech therapy has been proven in clinical trials to effectively improve spontaneous speech, auditory comprehension, repetition, and naming functions in patients with subacute and chronic aphasia following stroke. Building upon this therapy, this invention adds a module for collecting and differentiating the patient's five internal organ syndrome elements, creating a novel, online, therapist-free remote diagnosis and treatment software that integrates "patient symptom and sign information collection – five internal organ syndrome element assessment – ​​five-tone repertoire recommendation – active five-tone speech therapy – speech collection during training, accuracy and pronunciation standard assessment, training difficulty adjustment, scale evaluation, and training efficacy feedback." This invention can improve the applicability of Western classical melodic intonation therapy to Chinese aphasia patients, mobilize patients' subjective initiative, provide precise five-tone music recommendations and individualized treatment for patients with different syndrome types, enhance the rehabilitation effect and efficiency of existing speech training, reduce the workload of therapists, alleviate the medical and economic burden on patients, and lay the foundation for the development of subsequent active five-tone speech therapy remote diagnosis and treatment equipment.

This invention discloses a method and system for attention function intervention based on multi-sensory music. The method includes: obtaining the user's attention function assessment results; establishing a decision tree model to obtain the classification probabilities of each set attention function impairment type corresponding to the user; obtaining the user's human-computer interaction scheme based on multi-sensory music; obtaining the user's human-computer interaction results and evaluating their effectiveness; iterating the decision tree model based on the effectiveness evaluation results to update the classification probabilities of each set attention function impairment type corresponding to the user, and updating the human-computer interaction scheme, until the user passes the effectiveness evaluation of the human-computer interaction scheme. This method can effectively improve the user's attention function, not only by training a specific attention type, but also by emphasizing comprehensive training of different dimensions of attention. Patients with different attention disorders can choose appropriate music therapy to achieve improvement. The content is rich and diverse, meeting the intervention needs of different attention disorders.

A computer implemented method for determining a probability of a presence of pathology and / or functional disorder based on an acoustic recording of a lymphovenous junction, the method comprising; extracting a set of characteristic features from the acoustic recording, determining a set of quantitative values, such that, for each characteristic feature in the set of characteristic features, a quantitative value in the set of quantitative values indicate the characteristic feature's significance for the presence of pathology and / or functional disorder.

Provided herein are methods of using mesenchymal stromal / stem cell (MCS) exosomes in the treatment of diseases associated with thymic dysfunction. In some embodiments, the MSC exosomes restore thymic architecture and development in a subject having thymic dysfunction (e.g., caused by exposure to hyperoxia). In some embodiments, the subject is a human subject (e.g., a human neonate).

The invention relates to the technical field of biological medicine, and discloses a biomarker for predicting COPD cognitive impairment and application of the biomarker. The invention finds and verifies that the specificity of stearic acid (SA) in serum and a key enzyme ELOVL6 synthesized by the stearic acid (SA) in serum in a patient with secondary cognitive impairment (CI) of chronic obstructive pulmonary disease (COPD) is improved for the first time, the level of the stearic acid (SA) and the key enzyme ELOVL6 is negatively correlated with the cognitive impairment degree, and the stearic acid (SA) and the key enzyme ELOVL6 have good prediction efficiency (AUCgt, 0.82) on the COPD-CI. On the basis, the invention provides the application of the serum SA and / or ELOVL6 as the biomarker for predicting the COPD secondary CI risk, the in-vitro diagnostic kit comprising the detection reagent of the biomarker, and the method for predicting the risk by detecting the level of the marker. The invention provides a brand-new and reliable metabolic marker tool for early warning and intervention of CI of COPD patients, and has important clinical value and transformation prospect.

Subject measurement systems can generate indications of neurological state, disease, dysfunction, or injury using a machine learning model. The machine learning model can include at least one encoding model and a sequential model pre-trained to perform language processing tasks. The machine learning model can further include a classifier configured to output classifications. The at least one encoding model, sequential model, and at least one decoding model can be jointly trained to predict timeseries output, thereby adapting the pre-trained sequential model for use with neurologically relevant input domains, such as medical images, EEG data, evoked response data, speech data, or the like. The at least one encoding model, sequential model, and classifier can be jointly trained to output indications of neurological state, disease, dysfunction, or injury. A subject measurement system can then generate such indications using patient data and the at least one encoding model, sequential model, and classifier.

Provided herein are methods for detecting the risk or presence of a metabolic dysfunction or age-related disease in a subject. Also provided herein are methods for identifying a subject at risk or presence in need of treatment of metabolic dysfunction or age-related disease.

High-throughput screening (HTS) assays described herein rely on structural alterations triggered by cTnI phosphorylation during beta-adrenergic stimulation. These HTS assays may be used to pinpointsmall molecules that emulate phosphorylation effects, amplifying lusitropy by accelerating calcium dissociation from thin filaments. With a focus on addressing diastolic dysfunction, especially in conditions like HCM, the aim is to determine compounds tailored to modulate diastolic performance.

The present disclosure provides compositions and methods for treating and preventing localized nociception, inflammation, or morphological changes associated with joint disease or illness, back or spine conditions or disorders, and musculoskeletal diseases or dysfunction.

The invention relates to compounds of formula (I), wherein R1 is selected from the group consisting of H, C1-3-alkyl, C1-3-haloalkyl, -CH2-CO-NH2, -CH2-CO-NHCH3 and -CH2-CO-N(CH3)2 R2 is selected from the group consisting of H, halogen, (C1-3)-alkyl and halo-(C1-3)-alkyl, R3 is selected from the group consisting of C1-3-alkyl, five- or six-membered heterocyclic ring with 1 to 3 heteroatoms selected from N, O, S or SO2 and a five- or six-membered carbocyclic ring, wherein R3 is substituted by one or two substituents R8 which are each independently selected from the group consisting of H, C1-3-alkyl, -CO-O-(C1-4-alkyl), halogen, CN, OH, O-C1-3-methyl and -CO-(C1-3-alkyl), wherein each V, U, Q and T are independently from each other selected from C or N, wherein R4 is selected from the group consisting of H, halogen, -methyl, -O-C1-3-haloalkyl and -C1-3-haloalkyl, wherein R5 is selected from H, halogen, methyl, -O-C1-3-haloalkyl and -C1-3-haloalkyl, wherein R6 is selected from H, halogen, methyl, -O-C1-3-haloalkyl and -C1-3-haloalkyl, wherein R7 is selected from H, halogen, methyl, -O-C1-3-haloalkyl and -C1-3-haloalkyl, and pharmaceutical acceptable salts thereof, for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), interferonopathies, metabolic dysfunction associated Steatohepatitis (MASH), interstitial lung disease (ILD), decompensated liver cirrhosis and idiopathic pulmonary fibrosis (IPF).

Subject of the invention are DPP3 binders for use in therapy or prevention of endothelial dysfunction in a patient wherein the level of Pro-Adrenomedullin or a fragment thereof in a sample of bodily fluid obtained from said patient is above a threshold, as well as methods of therapy guidance or therapy stratification or therapy monitoring of a treatment of a patient with a DPP3 binder, the methods comprising: providing a sample of bodily fluid of said patient; determining the level of Pro-Adrenomedullin or a fragment thereof in said sample; and comparing said level of Pro-Adrenomedullin or a fragment thereof to a threshold; wherein the level of Pro-Adrenomedullin or a fragment thereof in said sample being above said threshold is indicative that said patient requires treatment with a DPP3 binder, or wherein if said level of Pro-Adrenomedullin or a fragment thereof in said sample is above said threshold, said patient is treated with a DPP3 binder.

Disclosed are compositions and methods for measuring olfactory sensitivity, olfactory resolution, and combinations thereof. Such measurements can be made during a single test, or over consecutive tests, which may be performed during a single testing period, such as in a single day, or over a series of testing periods. The tests may be performed by a health care professional, or may be conveniently self-administered by the user.

The application discloses application of an RB1 mutant in a neurodegenerative disease. The application finds through experiments that juvenile fish and adult heterozygotes of a zrb1-KO mutant zebrafish (2 bases are deleted at positions 67 and 68 of the 2nd exon of an rb1 gene) exhibit motor and memory learning dysfunction, exhibit increased post-mitotic neuron apoptosis in the hindbrain, and have the characteristics of a neurodegenerative disease, and therefore, the zrb1-KO mutant zebrafish can be used to construct an animal model of a neurodegenerative disease. In addition, the application also statistically analyzes the mutation frequency and mutation type of RB1 of a neurodegenerative disease patient, and verifies the pathogenicity of R621S and L819V mutations of RB1 in neuron apoptosis through experiments, thereby providing an effective approach for diagnosis or treatment of a neurodegenerative disease.